Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) therapy, which is the standard treatment for systemic ALK-positive and-negative ALCL, was shown to be transiently responsive but rapidly resistant; this is partially due to the inadequate penetration of the blood–brain barrier [63]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.